The Effects of Different Kinds of Antihypertensive Drugs on Blood Pressure Variability in Northern Chinese
Information source: First Affiliated Hospital of Harbin Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Indapamide (Drug); metoprolol (Drug); Irbesartan (Drug); amlodipine (Drug); Doxazosin (Drug)
Phase: Phase 2/Phase 3
Status: Recruiting
Sponsored by: First Affiliated Hospital of Harbin Medical University Overall contact:
Yue Li, PHD, Phone: 86-451-85555673, Email: ly99ly@vip.163.com
Summary
Hypertension is one of the most common cardiovascular diseases, which is a major risk factor
for stroke and cardiovascular events. Traditionally, cardiovascular risk stratification in
hypertensive patients was based on the average blood pressure (BP) measured in the clinic.
Accumulated data has shown that target-organ damage is related not only to 24-h mean
intra-arterial BP, but also to BP variability (BPV) in subjects with essential hypertension.
Growing evidence demonstrated that BPV has considerable prognostic value for all-cause
mortality and cardiovascular outcomes, independent of average BP.
At present, the normal range of BPV is not very clear. There are many studies about the
effects of different kinds of drugs on blood pressure, but the clinical researches about the
impacts of antihypertensive drugs on BPV are limited, and the conclusion is still
controversial.
Clinical Details
Official title: The Effects of Different Kinds of Antihypertensive Drugs on Blood Pressure Variability in Northern Chinese: a Randomized Controlled Study
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: 24-hour Ambulatory Blood Pressure Monitoring
Secondary outcome: plasma uric acid level
Detailed description:
Hypertension is one of the most common cardiovascular diseases, which is a major risk factor
for stroke and cardiovascular events. Traditionally, cardiovascular risk stratification in
hypertensive patients was based on the average blood pressure (BP) measured in the clinic.
Accumulated data has shown that target-organ damage is related not only to 24-h mean
intra-arterial BP, but also to BP variability (BPV) in subjects with essential hypertension.
Growing evidence demonstrated that BPV has considerable prognostic value for all-cause
mortality and cardiovascular outcomes, independent of average BP.
The hypertension prevalences in the high latitude and cold regions are much higher than
those in the low latitude and warm regions. In China, the prevalences of hypertension are
gradually increased from the South to the North. Heilongjiang province is the "high-risk"
region for hypertension, with a prevalence of 30. 48%. This may be due to the combined
effects of lower average temperature and higher intake of salt and saturated fatty acid,
which Increased sympathetic nerve excitability, and eventually lead to elevation of blood
pressure. Therefore, it is essential to formulate the best treatment of hypertension
according with the physical characteristics of northern Chinese.
At present, the normal range of BPV is not very clear. There are many studies about the
effects of different kinds of drugs on blood pressure, but the clinical researches about the
impacts of antihypertensive drugs on BPV are limited, and the conclusion is still
controversial.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men aged between 18 and 75 included years old
- Postmenopausal women who are no more than 75 years older.
- Patients with essential mild to moderate uncomplicated hypertension (DBP＜110mmHg and
SBP＜180mmHg measured with a validated automatic device in sitting position) after
initiation or intensification of appropriate healthy lifestyle modification,
- Without antihypertensive treatment in 2 weeks.
Exclusion Criteria:
- History of cerebrovascular disease: ischemic stroke, cerebral haemorrhage and TIA.
- History of cardiovascular disease: unstable angina, myocardial infarction, coronary
revascularization and congestive heart failure.
- History of renal impairment.
- History of Type I diabetes mellitus or Type II diabetes uncontrolled.
- History of liver impairment.
- History of alcoholism or drug abuse.
- Known symptomatic orthostatic hypotension.
- Contra-indications to treatment with investigate products.
Locations and Contacts
Yue Li, PHD, Phone: 86-451-85555673, Email: ly99ly@vip.163.com
Twenty-four-hour ambulatory BP monitoring, Budapest, Hungary; Recruiting
Jingyan Piao, MM, Phone: 86-451-85555333, Email: 411483521@qq.com
Yujiao Pan, MM, Phone: 86-451-85555671, Email: panyujiao@163.com
Additional Information
Starting date: July 2015
Last updated: July 30, 2015
|
